Skip to main content
. Author manuscript; available in PMC: 2024 Apr 17.
Published in final edited form as: Lancet. 2023 Apr 15;401(10384):1277–1292. doi: 10.1016/S0140-6736(23)00285-4

Figure 2: 10-year cumulative risk of outcomes with taxane plus anthracycline versus taxane without anthracycline.

Figure 2:

All analyses included 18 103 participants (9076 in taxane plus anthracycline group, 9027 in taxane only group). 10-year cumulative risk of any invasive recurrence (A), breast cancer mortality (B), death without recurrence (C)*, and any death (D)*. Error bars show 95% CI. O–E=observed minus expected. RR=rate ratio. V=variance. 2p=two-sided p value. *Smoothed after 5 years (denoted by dotted line).